A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Site TW88605, Kaohsiung City

Site TW88603, Taipei

Site IT39002, Roma

Site PT35106, Coimbra

Site KR82013, Goyang

Site GR30010, Athens

Site RS38102, Belgrade

Site US10025, Syracuse

Site KR82014, Bucheon-si

Site KR82005, Suwon

Site IT39011, Milan

Site IT39008, Bergamo

Site US10029, Greenville

Site FR33004, Brest

Site IT39004, Castelfranco Veneto (TV)

Site US10030, Jacksonville

Site FR33002, Tours

Site IT39010, Reggio Emilia

Site DE49001, Duisburg

Site KR82006, Busan

Site FR33014, Vandœuvre-lès-Nancy

Site GR30004, Thessaloniki

Site KR82003, Hwasungun

Site US10012, Chicago

Site FR33001, Bayonne

Site FR33009, Mulhouse

Site FR33007, Pierre-Bénite

Site DE49008, Stuttgart

Site CZ42001, Ostrava-Poruba

Site TW88604, Kaohsiung City

Site IL97205, Jerusalem

Site US10007, Portland

Site US10017, Gainesville

Site BR55002, Goiânia

Site CA15001, Halifax

Site CA15003, Toronto

Site DK45002, Aarhus

Site FR33008, Nice

Site GR30009, Athens

Site GR30007, Larissa

Site IT39005, Parma

Site JP81018, Nagoya

Site JP81025, Matsuyama

Site JP81002, Yoshida-gun

Site JP81024, Sapporo

Site JP81012, Kobe

Site JP81004, Kanazawa

Site JP81009, Yokohama

Site JP81014, Sendai

Site JP81023, Shimotsuke

Site JP81011, Tachikawa

Site JP81010, Aomori

Site JP81017, Okayama

Site PL48007, Poznan

Site RO40005, Bucharest

Site HU36003, Nyíregyháza

Site PL48001, Olsztyn

Site PL48002, Bydgoszcz

Site PT35101, Porto

Site KR82008, Namdong

Site KR82012, Seoul

Site KR82009, Seoul

Site ES34009, Vitoria-Gasteiz

Site SE46003, Stockholm

Site SE46002, Lund

Site GB44007, Exeter

Site GB44019, Plymouth

Site GB44006, Cottingham

Site GB44018, London

Site GB44002, Birmingham

Site GB44015, Cardiff

Site GB44020, Leeds

Site GB44004, Nottingham